Collectively, our findings reveal a previously unrecognized mechanism underlying sunitinib resistance in ccRCC and highlight CYP1B1 as a promising therapeutic target for overcoming resistance to TKIs. This evidence concerns the gene CYP1B1 and nonpapillary renal cell carcinoma.